The Carcinogenic Potency Project

1,3-Butadiene (CAS 106-99-0)
SMILES, InChI and Structure are below.
Rats and Mice: Cancer Test Summary
Rat Target Sites Mouse Target Sites TD50 (mg/kg/day)
Male Female Male Female Rat Mouse
tes mgl hag hmo kid liv lun nrv pre sto vsc hag hmo liv lun mgl ova sto vsc 261m,v 13.9m,v

Key to the Table Above

Positivity: For each chemical with a positive (carcinogenic) experiment in the Carcinogenic Potency Database (CPDB), results are included on carcinogenic potency (TD50) in each species and target sites in males and females. Positivity is determined by an author’s opinion in a published paper. If all experimental results in the CDPB are negative in a sex-species group, “no positive” appears. If the CPDB has no experiments in the sex-species group, “no test” appears. The summary presents the strongest evidence of carcinogenicity in each group. If there are both positive and negative experiments in a sex-species, the negative results are ignored in this Summary Table.
Target Site Codes:   hag = harderian gland. hmo = hematopoietic system. kid = kidney. liv = liver. lun = lung. mgl = mammary gland. nrv = nervous system. ova = ovary. pre = preputial gland. sto = stomach. tes = testes. vsc = vascular system. Target sites are listed if any author of published experimental results concluded that tumors were induced in that organ by the test agent. If there is more than one positive experiment in a sex-species, target sites listed may be from more than one experiment, e.g. if liver and lung are both listed, then liver may have been a target in one experiment and lung in another.
TD50: Our standardized measure of carcinogenic potency, TD50, is the daily dose rate in mg/kg body weight/day to induce tumors in half of test animals that would have remained tumor-free at zero dose. Whenever there is more than one positive experiment in a species, the reported TD50 value is a Harmonic Mean calculated using the TD50 value from the most potent target site in each positive experiment.
Superscripts:   m = There is more than one positive experiment in the species, and TD50 values from each positive experiment are used in the calculation of the reported Harmonic mean of TD50. v = Variation is greater than ten-fold among statistically significant (two-tailed p<0.1) TD50 values from different positive experiments.

The Carcinogenic Potency Database (CPDB) is a unique and widely used international resource of the results of 6540 chronic, long-term animal cancer tests on 1547 chemicals. The CPDB provides easy access to the bioassay literature, with qualitative and quantitative analyses of both positive and negative experiments that have been published over the past 50 years in the general literature through 2001 and by the National Cancer Institute/National Toxicology Program through 2004. The CPDB standardizes the diverse literature of cancer bioassays that vary widely in protocol, histopathological examination and nomenclature, and in the published author’s choices of what information to provide in their papers. Results are reported in the CPDB for tests in rats, mice, hamsters, dogs, and nonhuman primates.

For each experiment, information is included on species, strain, and sex of test animal; features of experimental protocol such as route of administration, duration of dosing, dose level(s) in mg/kg body weight/day, and duration of experiment; experimental results are provided on target organ, tumor type, and tumor incidence; carcinogenic potency (TD50) and its statistical significance; shape of the dose-response, author’s opinion as to carcinogenicity, and literature citation.

Only tests with dosing for at least ¼ the standard lifespan of the species and experiment length at least ½ the lifespan are included in the CPDB. Only routes of administration with whole body exposure are included. Doses are standardized, average dose rates in mg/kg/day. A description of methods used in the CPDB to standardize the diverse literature of animal cancer tests is presented for: 1) Criteria for inclusion of experiments 2) Standardization of average daily dose levels and 3) TD50 estimation for a standard lifespan. See Methods for other details.

TD50 provides a standardized quantitative measure that can be used for comparisons and analyses of many issues in carcinogenesis. The range of TD50 values across chemicals that are rodent carcinogens is more than 100 million-fold. More than half the chemicals tested are positive in at least one experiment.

A plot of all results on each experiment in the CPDB for this chemical is presented below. These results are the source information for the Cancer Test Summary table above.

1,3-Butadiene: All Experiments and Citations in CPDB

The definition of each code in the plot below will appear in a pop-up window when the field name in the header line is clicked, e.g., Strain, Site, Path. Each numbered line starts a new experiment and reports protocol information in black. Average daily dose-rates per kg body weight per day are in green. Remaining lines report experimental results in blue.

Abbreviations of fields in header line: # = the line number in the plot of all CPDB chemicals; Xpo = duration of dosing; Xpt = duration of experiment; Site = tissue; Path = tumor type; DR = dose-response; AuOp = author’s opinion about carcinogenicity; LoConf, UpConf = confidence limits (99%) on TD50; Inc = tumor incidence for each dose group.

See Guide to reading the plot for details on each field, using an example of one experiment.

See Help to improve readability, or to fit the plot onto the screen or a printed page.



Chemical (Synonym) CAS
# Species Sex Strain Route Xpo+Xpt PaperNum        0 Dose  1 Dose 2 Dose  3 Dose          Literature Reference or NCI/NTP:Site Path
Site Path Notes   TD50  DR Pval    AuOp LoConf UpConf   Cntrl   1 Inc  2 Inc   3 Inc                                                        Brkly Code



1,3-BUTADIENE   106-99-0
867  M f b6c inh 61w61 TR288 :                       0    435.mg  869.mg
 MXB MXB        53.0mg \ P<.0005    30.6mg 106.mg   4/50   30/50  (44/50)     ---:mno; for:sqp; hea:hes; liv:hpa,hpc; lun:a/a,a/c;
                                                                                                             mgl:acc; ova:gcc,gct. C
 MXA hes        147.mg \ P<.0005    73.4mg 333.mg   0/50   13/50  (19/50)                               hea:hes; liv:hes; sub:hes. S
 lun MXA        203.mg * P<.0005 c  126.mg 411.mg   3/50   12/50   23/50                                              lun:a/a,a/c.
 lun a/c        227.mg \ P<.0005 c  91.8mg 825.mg   0/50    6/50   (8/50)
 lun a/a        259.mg * P<.0005 c  153.mg 585.mg   3/50    9/50   20/50
 --- mno        270.mg \ P<.0005 c  114.mg 1.03gm   1/50   10/50  (10/50)
 hea hes        283.mg * P<.0005 c  179.mg 483.mg   0/50   11/50   18/50
 ova MXA        370.mg * P<.0005 c  214.mg 728.mg   0/50    6/50   13/50                                              ova:gcc,gct.
 for MXA        396.mg \ P<.002     133.mg 2.44gm   0/50    4/50   (1/50)                                             for:sqc,sqp. S
 for sqp        461.mg \ P<.005  c  140.mg 5.15gm   0/50    3/50   (1/50)
 for MXA        462.mg * P<.0005    252.mg 1.03gm   0/50    5/50   10/50                                          for:ppn,sqc,sqp. S
 for MXA        483.mg * P<.0005    259.mg 1.10gm   0/50    4/50   10/50                                              for:ppn,sqp. S
 mgl acc        1.03gm * P<.002  c  462.mg 4.19gm   0/50    2/50    6/50
 liv MXA        1.17gm * P<.004  c  496.mg 6.82gm   0/50    2/50    5/50                                              liv:hpa,hpc.
 liv hpa        1.59gm * P<.009  c  596.mg 36.9gm   0/50    1/50    4/50
 ova gcc        7.58gm * P<.2    c  1.23gm n.s.s.   0/50    0/50    1/50
 TBA MXB        41.5mg \ P<.0005    25.1mg 75.8mg   6/50   40/50  (46/50)
 liv MXB        1.17gm * P<.004     496.mg 6.82gm   0/50    2/50    5/50                                          liv:hpa,hpc,nnd.
 lun MXB        203.mg * P<.0005    126.mg 411.mg   3/50   12/50   23/50                                              lun:a/a,a/c.
868  M f b6c inh 19m24 TR434 :                       0    4.26mg  13.7mg  42.8mg  139.mg  435.mg
 MXB MXB a      6.79mg Z P<.0005    4.92mg 9.63mg  28/50   36/50   39/50   45/50   48/50   71/80     ---:hcs,mlm,mlp,mlu,mly; for:
                                sqc,sqp; hag:adc,ade,anb; hea:hes; liv:hpa,hpc; lun:a/a,a/c,adc; mgl:adc,ado,mtm; ova:ade,gcb,gcm,
                                                                                                                              mtb. C
 lun MXA a      12.4mg Z P<.0005 c  8.55mg 19.5mg   4/50   15/50   19/50   24/50   25/50   22/80                  lun:a/a,a/c,adc.
 lun a/a a      20.3mg Z P<.0005    12.9mg 35.5mg   4/50   11/50   12/50   17/50   14/50   17/80                                   S
 liv MXA a      22.8mg * P<.0005 c  13.7mg 44.6mg  15/50   14/50   15/50   19/50   16/50    2/80                      liv:hpa,hpc.
 lun MXA a      23.9mg Z P<.0005    15.3mg 39.1mg   0/50    5/50   11/50    9/50   19/50    8/80                      lun:a/c,adc. S
 hag MXA a      26.2mg Z P<.0005 c  16.1mg 47.2mg   8/50   10/50    7/50   15/50   20/50    9/80                  hag:adc,ade,anb.
 hag MXA a      26.2mg Z P<.0005    16.1mg 47.3mg   8/50   10/50    6/50   15/50   20/50    9/80                      hag:ade,anb. S
 --- MXA a      27.4mg Z P<.0005    16.3mg 50.9mg   9/50   14/50   18/50   11/50   16/50   36/80          ---:hcs,mlm,mlp,mlu,mly. S
 liv hpa a      28.5mg Z P<.0005    16.3mg 61.6mg  11/50   10/50    9/50   14/50   12/50   (1/80)                                  S
 --- MXA a      35.0mg Z P<.0005    21.6mg 59.1mg   5/50    3/50    3/50    9/50   24/50   27/80                      ---:hem,hes. S
 --- MXA a      35.2mg Z P<.0005 c  19.6mg 74.7mg   6/50   12/50   11/50    7/50    9/50   32/80              ---:mlm,mlp,mlu,mly.
 --- hes a      44.2mg Z P<.0005    26.3mg 75.0mg   3/50    2/50    2/50    5/50   23/50   27/80                                   S
 mgl MXA a      47.4mg * P<.0005 c  28.0mg 80.9mg   0/50    2/50    4/50   12/50   15/50   16/80                  mgl:adc,ado,mtm.
 liv hpc a      50.5mg * P<.0005    26.6mg 125.mg   4/50    6/50    8/50    9/50    8/50    1/80                                   S
 ova MXA a      65.4mg * P<.0005 c  34.9mg 133.mg   1/50    0/50    1/50    9/50    8/50    6/80                      ova:gcb,gcm.
 --- mlp a      74.9mg * P<.0005 c  36.6mg 171.mg   1/50    3/50    6/50    3/50    8/50   31/80
 ova MXA a      78.9mg * P<.0005 c  35.1mg 256.mg   2/50    4/50    1/50    4/50    6/50    2/80                      ova:ade,mtb.
 for MXA a      83.9mg Z P<.0005 c  39.8mg 192.mg   0/50    0/50    3/50    2/50    4/50   22/80                      for:sqc,sqp.
 mgl ado a      87.7mg * P<.0005    40.5mg 237.mg   0/50    1/50    2/50    6/50    4/50    0/80                                   S
 mgl adc a      93.3mg * P<.0005    49.3mg 174.mg   0/50    2/50    2/50    6/50   11/50   12/80                                   S
 ova MXA a      98.0mg * P<.0005    47.4mg 235.mg   1/50    0/50    1/50    6/50    6/50    6/80                      ova:gcb,glb. S
 hea hes a      104.mg Z P<.0005 c  60.0mg 161.mg   0/50    0/50    0/50    1/50   21/50   23/80
 --- hcs a      125.mg * P<.0005 c  54.2mg 431.mg   3/50    2/50    7/50    4/50    7/50    4/80
 for sqp a      126.mg Z P<.0005    51.7mg 337.mg   0/50    0/50    2/50    1/50    3/50   16/80                                   S
 sub MXA a      128.mg * P<.0005 e  57.9mg 434.mg   1/50    2/50    3/50    5/50    3/50    3/80                      sub:nfs,sar.
 sub sar a      131.mg * P<.0005    58.8mg 437.mg   1/50    2/50    2/50    5/50    3/50    3/80                                   S
 ova gcm a      198.mg * P<.0005    68.7mg 790.mg   0/50    0/50    0/50    3/50    2/50    0/80                                   S
 ova mtb a      202.mg * P<.0005    73.1mg 622.mg   0/50    0/50    0/50    2/50    5/50    1/80                                   S
 for sqc a      257.mg * P<.0005    77.9mg 1.04gm   0/50    0/50    1/50    1/50    1/50    6/80                                   S
 kid rua a      1.06gm * P<.01   e  199.mg 246.gm   0/50    0/50    0/50    0/50    2/50    0/80
 mgl mtm a      2.71gm * P<.0005    869.mg 13.2gm   0/50    0/50    0/50    0/50    0/50    4/80                                   S
 zym MXA a      3.54gm * P<.004  e  808.mg 55.7gm   0/50    0/50    0/50    0/50    0/50    2/80                      zym:ade,car.
 ova ade a      217.mg * P<.03      55.2mg n.s.s.   2/50    4/50    1/50    2/50    1/50    1/80                                   S
 TBA MXB a      6.28mg Z P<.0005    4.65mg 8.91mg  35/50   47/50   43/50   48/50   49/50   72/80
 liv MXB a      22.8mg * P<.0005    13.7mg 44.6mg  15/50   14/50   15/50   19/50   16/50    2/80                  liv:hpa,hpc,nnd.
 lun MXB a      13.8mg Z P<.0005    9.48mg 21.9mg   4/50   13/50   18/50   22/50   24/50   22/80                      lun:a/a,a/c.
869  M m b6c inh 60w60 TR288 :                       0    362.mg  724.mg
 MXB MXB        28.8mg \ P<.0005    17.5mg 50.0mg   2/50   43/50  (39/50)              ---:mno; for:ppn,sqp; hea:hes; lun:a/a,a/c. C
 lun MXA        65.9mg * P<.0005 c  38.7mg 128.mg   2/50   14/50   15/50                                              lun:a/a,a/c.
 hea hes        96.7mg \ P<.0005 c  51.1mg 198.mg   0/50   16/50   (7/50)
 MXA hes        96.7mg \ P<.0005    51.1mg 198.mg   0/50   16/50   (8/50)                                        hea:hes; pec:hes. S
 lun a/a        96.9mg * P<.0005 c  54.4mg 203.mg   2/50   12/50   11/50
 --- mno        105.mg * P<.0005 c  70.1mg 158.mg   0/50   23/50   29/50
 for MXA        120.mg \ P<.0005    49.6mg 391.mg   0/50    7/50   (1/50)                                         for:ppn,sqc,sqp. S
 for MXA        140.mg \ P<.0005 c  53.3mg 600.mg   0/50    5/50   (0/50)                                             for:ppn,sqp.
 lun a/c        312.mg * P<.0005 c  126.mg 1.08gm   0/50    2/50    5/50
 pre MXA        403.mg * P<.002     150.mg 1.92gm   0/50    3/50    2/50                                              pre:can,sqc. S
 pre sqc        538.mg * P<.004     181.mg 4.83gm   0/50    3/50    1/50                                                           S
 for MXA        557.mg * P<.004     197.mg 4.31gm   0/50    4/50    1/50                                              for:sqc,sqp. S
 TBA MXB        28.8mg \ P<.0005    17.3mg 52.5mg  10/50   44/50  (40/50)
 liv MXB        541.mg * P<.2       149.mg n.s.s.   8/50    6/50    2/50                                          liv:hpa,hpc,nnd.
 lun MXB        65.9mg * P<.0005    38.7mg 128.mg   2/50   14/50   15/50                                              lun:a/a,a/c.
870  M m b6c inh 19m24 TR434 :                       0    3.55mg  11.4mg  35.6mg  114.mg  362.mg
 MXB MXB a      10.7mg Z P<.0005    7.80mg 15.3mg  42/50   38/50   44/50   47/50   49/50   62/73      ---:hcs,mlh,mlm,mlp,mlu,mly;
                                            for:sqc,sqp; hag:adc,ade,anb; hea:hes; kid:rua; liv:hpa,hpc; lun:a/a,a/c,adc; pre:car. C
 lun MXA a      19.2mg * P<.0005 c  12.6mg 32.9mg  21/50   23/50   19/50   31/50   35/50    3/73                  lun:a/a,a/c,adc.
 liv MXA a      23.9mg Z P<.0005 c  14.9mg 43.3mg  21/50   23/50   30/50   25/50   33/50    5/73                      liv:hpa,hpc.
 hag MXA a      26.1mg Z P<.0005 c  17.5mg 41.5mg   6/50    7/50    9/50   20/50   31/50    6/73                  hag:adc,ade,anb.
 hag MXA a      27.6mg Z P<.0005    18.4mg 45.0mg   6/50    7/50    8/50   19/50   30/50    6/73                      hag:ade,anb. S
 lun MXA a      32.4mg Z P<.0005    20.5mg 58.0mg   5/50    6/50   11/50   12/50   22/50    3/73                      lun:a/c,adc. S
 lun a/a a      33.2mg * P<.0005    19.7mg 69.3mg  18/50   20/50   10/50   25/50   21/50    3/73                                   S
 liv hpa a      34.1mg Z P<.0005    20.5mg 65.6mg  13/50   13/50   19/50   16/50   24/50    5/73                                   S
 liv hpc a      34.4mg * P<.0005    20.5mg 68.2mg  11/50   16/50   16/50   17/50   26/50    1/73                                   S
 --- MXA a      38.0mg Z P<.0005    24.5mg 63.4mg   2/50    5/50    3/50   11/50   24/50    4/73                      ---:hem,hes. S
 --- hes a      45.5mg Z P<.0005    28.6mg 78.7mg   1/50    4/50    3/50    7/50   24/50    4/73                                   S
 --- MXA a      63.5mg Z P<.0005    40.8mg 101.mg   4/50    2/50    8/50   11/50    9/50   55/73      ---:hcs,mlh,mlm,mlp,mlu,mly. S
 hea hes a      64.8mg Z P<.0005 c  38.8mg 114.mg   0/50    0/50    1/50    5/50   20/50    4/73
 --- MXA a      99.8mg Z P<.0005 c  60.0mg 174.mg   4/50    2/50    4/50    6/50    2/50   51/73          ---:mlh,mlm,mlp,mlu,mly.
 --- hcs a      157.mg * P<.0005 c  82.9mg 372.mg   0/50    0/50    4/50    5/50    7/50    4/73
 --- mlp a      157.mg Z P<.0005 c  93.7mg 248.mg   2/50    0/50    2/50    4/50    2/50   49/73
 for MXA a      197.mg Z P<.0005 c  91.0mg 494.mg   1/50    0/50    0/50    1/50    8/50    4/73                      for:sqc,sqp.
 hag adc a      221.mg * P<.005     85.7mg 3.26gm   0/50    1/50    1/50    3/50    2/50    0/73                                   S
 for sqp a      230.mg Z P<.0005    98.7mg 674.mg   1/50    0/50    0/50    1/50    7/50    2/73                                   S
 pre car a      384.mg * P<.0005 c  131.mg 1.52gm   0/50    0/50    0/50    0/50    5/50    0/73
 kid rua a      268.mg * P<.02   c  92.1mg n.s.s.   0/50    1/50    0/50    3/50    1/50    0/73
 jej car a      310.mg * P<.02   e  97.0mg n.s.s.   0/50    1/50    1/50    1/50    2/50    0/73
 sub hes a      666.mg * P<.03      164.mg n.s.s.   0/50    1/50    1/50    0/50    3/50    0/73                                   S
 bra onm a      no dre   P=1.       n.s.s. n.s.s.   0/50    0/50    0/50    0/50    0/50    0/73
 bra ogm a      no dre   P=1.       n.s.s. n.s.s.   0/50    0/50    0/50    0/50    0/50    0/73
 TBA MXB a      10.5mg Z P<.0005    7.76mg 15.1mg  44/50   40/50   45/50   48/50   49/50   62/73
 liv MXB a      23.9mg Z P<.0005    14.9mg 43.3mg  21/50   23/50   30/50   25/50   33/50    5/73                  liv:hpa,hpc,nnd.
 lun MXB a      19.6mg * P<.0005    12.8mg 33.8mg  21/50   23/50   18/50   30/50   35/50    3/73                      lun:a/a,a/c.
871  M m b6c inh 12m24 TR434a :                      0    90.3mg
 MXB MXB        6.12mg   P<.0005    3.14mg 12.8mg  38/50   50/50   ---:hcs,mlm,mlp,mly; for:sqc,sqp; hag:adc,ade,adi,anb; hea:hes;
                                                                               kid:ade,rua; liv:hpa; lun:a/a,a/c,adc; pre:car,cnb. C
 lun MXA        7.17mg   P<.0005 c  3.25mg 17.2mg  21/50   32/50                                                  lun:a/a,a/c,adc.
 lun a/a        9.13mg   P<.0005    3.90mg 24.2mg  18/50   26/50                                                                   S
 --- MXA        11.1mg   P<.0005    3.83mg 29.2mg   2/50   34/50                                                      ---:hem,hes. S
 --- hes        11.9mg   P<.0005    3.99mg 30.6mg   1/50   34/50                                                                   S
 lun MXA        13.0mg   P<.0005    4.19mg 45.1mg   5/50   16/50                                                      lun:a/c,adc. S
 hag MXA        13.1mg   P<.0005 c  5.55mg 30.1mg   6/50   30/50                                              hag:adc,ade,adi,anb.
 liv MXA        13.8mg   P<.0005    5.73mg 38.4mg  21/50   25/50                                                  liv:hpa,hpb,hpc. S
 hea hes        13.9mg   P<.0005 c  4.42mg 30.6mg   0/50   33/50
 liv MXA        14.6mg   P<.0005    5.90mg 42.0mg  21/50   24/50                                                      liv:hpa,hpc. S
 hag MXA        14.9mg   P<.0005    5.97mg 35.0mg   6/50   28/50                                                      hag:ade,anb. S
 liv hpa        15.8mg   P<.0005 c  5.76mg 51.1mg  13/50   19/50
 pre MXA        20.1mg   P<.0005 c  4.83mg 145.mg   0/50    4/50                                                      pre:car,cnb.
 --- MXA        27.6mg   P<.0005    7.97mg 102.mg   4/50   15/50                                              ---:hcs,mlm,mlp,mly. S
 liv MXA        41.4mg   P<.0005    13.5mg 226.mg  11/50   11/50                                                      liv:hpb,hpc. S
 for MXA        42.8mg   P<.0005 c  7.30mg 203.mg   1/50    9/50                                                      for:sqc,sqp.
 --- MXA        46.4mg   P<.0005 c  9.93mg 342.mg   4/50    8/50                                                  ---:mlm,mlp,mly.
 liv hpc        47.0mg   P<.002     14.4mg 341.mg  11/50   10/50                                                                   S
 --- MXA        76.2mg   P<.006     14.4mg 2.13gm   2/50    4/50                                                      ---:mlm,mly. S
 for sqp        77.7mg   P<.004     8.51mg 1.67gm   1/50    4/50                                                                   S
 hag MXA        88.9mg   P<.007     15.0mg 1.69gm   0/50    2/50                                                      hag:adc,adi. S
 --- hcs        110.mg   P<.0005 c  32.2mg 434.mg   0/50    7/50
 for sqc        154.mg   P<.0005    54.0mg 670.mg   0/50    5/50                                                                   S
 kid MXA        190.mg   P<.003  c  44.1mg 2.09gm   0/50    3/50                                                      kid:ade,rua.
 --- mlp        129.mg   P<.03   c  12.9mg n.s.s.   2/50    4/50
 bra onm        no dre   P=1.       n.s.s. n.s.s.   0/50    0/50
 bra ogm        no dre   P=1.       n.s.s. n.s.s.   0/50    0/50
 --- hem        no dre   P=1.       18.8mg n.s.s.   1/50    0/50
 zym ade        no dre   P=1.       18.8mg n.s.s.   1/50    0/50
 zym car        no dre   P=1.       n.s.s. n.s.s.   0/50    0/50
 TBA MXB        5.84mg   P<.0005    3.03mg 12.3mg  44/50   50/50
 liv MXB        14.6mg   P<.0005    5.90mg 42.0mg  21/50   24/50                                                  liv:hpa,hpc,nnd.
 lun MXB        7.25mg   P<.0005    3.27mg 17.6mg  21/50   31/50                                                      lun:a/a,a/c.
872  M m b6c inh  9m24 TR434b :                      0    44.5mg
 MXB MXB        10.9mg   P<.0005    5.96mg 27.1mg  38/50   47/50  ---:hcs,mlm,mlp,mly; for:sqc,sqp; hag:adc,ade,anb; hea:hes; kid:
                                                                                           rua; liv:hpa; lun:a/a,a/c; pre:car,cnb. C
 lun MXA        11.0mg   P<.0005 c  5.99mg 25.4mg  21/50   36/50                                                      lun:a/a,a/c.
 lun a/c        16.3mg   P<.0005    8.37mg 38.5mg   5/50   22/50                                                                   S
 liv MXA        16.8mg   P<.0005    8.75mg 44.4mg  21/50   33/50                                                      liv:hpa,hpc. S
 --- MXA        17.3mg   P<.0005    9.19mg 38.5mg   2/50   20/50                                                      ---:hem,hes. S
 hag MXA        17.5mg   P<.0005 c  9.53mg 37.5mg   6/50   27/50                                                  hag:adc,ade,anb.
 hag MXA        18.0mg   P<.0005    9.67mg 39.1mg   6/50   26/50                                                      hag:ade,anb. S
 liv hpa        18.0mg   P<.0005 c  9.14mg 46.7mg  13/50   27/50
 lun a/a        18.1mg   P<.0005    8.53mg 63.0mg  18/50   24/50                                                                   S
 --- hes        20.8mg   P<.0005    10.8mg 47.6mg   1/50   17/50                                                                   S
 hea hes        21.9mg   P<.0005 c  11.1mg 48.2mg   0/50   15/50
 --- MXA        57.1mg   P<.002     24.5mg 259.mg   4/50   13/50                                              ---:hcs,mlm,mlp,mly. S
 --- hcs        128.mg   P<.002  c  44.7mg 670.mg   0/50    5/50
 kid rua        161.mg   P<.005  c  49.3mg 1.60gm   0/50    4/50
 liv hpc        62.0mg   P<.02      23.9mg n.s.s.  11/50   14/50                                                                   S
 --- hem        95.2mg   P<.02      27.8mg n.s.s.   1/50    4/50                                                                   S
 --- MXA        108.mg   P<.03   c  34.5mg n.s.s.   4/50    8/50                                                  ---:mlm,mlp,mly.
 --- mlp        142.mg   P<.04   c  41.0mg n.s.s.   2/50    6/50
 for sqp        171.mg   P<.06      41.5mg n.s.s.   1/50    3/50
 for MXA        171.mg   P<.06   c  41.5mg n.s.s.   1/50    3/50                                                      for:sqc,sqp.
 pre MXA        351.mg   P<.1       57.1mg n.s.s.   0/50    1/50                                                  pre:ade,car,cnb.
 pre MXA        351.mg   P<.1    c  57.1mg n.s.s.   0/50    1/50                                                      pre:car,cnb.
 hag adc        531.mg   P<.07      130.mg n.s.s.   0/50    2/50
 --- MXA        487.mg   P<.5       63.3mg n.s.s.   2/50    2/50                                                      ---:mlm,mly.
 zym car        625.mg   P<.2       102.mg n.s.s.   0/50    1/50
 zym MXA        647.mg   P<.5       62.7mg n.s.s.   1/50    1/50                                                      zym:ade,car.
 bra onm        no dre   P=1.       n.s.s. n.s.s.   0/50    0/50
 bra ogm        no dre   P=1.       n.s.s. n.s.s.   0/50    0/50
 TBA MXB        10.8mg   P<.0005    5.83mg 28.7mg  44/50   49/50
 liv MXB        16.8mg   P<.0005    8.75mg 44.4mg  21/50   33/50                                                  liv:hpa,hpc,nnd.
 lun MXB        11.0mg   P<.0005    5.99mg 25.4mg  21/50   36/50                                                      lun:a/a,a/c.
873  M m b6c inh  6m24 TR434c :                      0    90.5mg
 MXB MXB        12.6mg   P<.0005    6.27mg 24.4mg  38/50   49/50   ---:hcs,mlm,mlp,mly; bra:ogm; for:sqc,sqp; hag:adc,ade,adi,anb;
                                                                              hea:hes; kid:rua; liv:hpa; lun:a/a,a/c; pre:car,cnb. C
 lun MXA        13.4mg   P<.0005 c  5.01mg 36.8mg  21/50   17/50                                                      lun:a/a,a/c.
 lun a/a        17.3mg   P<.0005    5.62mg 57.0mg  18/50   12/50                                                                   S
 --- hes        17.7mg   P<.0005    4.72mg 56.1mg   1/50   14/50                                                                   S
 --- MXA        17.7mg   P<.0005    4.72mg 56.1mg   2/50   14/50                                                      ---:hem,hes. S
 lun a/c        17.8mg   P<.0005    4.74mg 62.0mg   5/50   11/50                                                                   S
 hea hes        18.5mg   P<.0005 c  4.76mg 64.3mg   0/50   13/50
 hag MXA        22.7mg   P<.0005    6.72mg 71.9mg   6/50   13/50                                                      hag:ade,anb. S
 hag MXA        22.7mg   P<.0005 c  6.72mg 71.9mg   6/50   13/50                                              hag:adc,ade,adi,anb.
 liv MXA        23.8mg   P<.0005    8.28mg 77.1mg  21/50   13/50                                                      liv:hpa,hpc. S
 liv MXA        23.8mg   P<.0005    8.28mg 77.1mg  21/50   13/50                                                  liv:hpa,hpb,hpc. S
 pre MXA        27.1mg   P<.0005 c  4.99mg 390.mg   0/50    3/50                                                      pre:car,cnb.
 pre MXA        27.1mg   P<.0005    4.99mg 390.mg   0/50    3/50                                                  pre:ade,car,cnb. S
 liv hpa        27.8mg   P<.0005 c  8.53mg 103.mg  13/50   11/50
 --- MXA        28.8mg   P<.0005    13.0mg 55.5mg   4/50   35/50                                              ---:hcs,mlm,mlp,mly. S
 --- MXA        31.3mg   P<.0005 c  13.5mg 62.6mg   4/50   33/50                                                  ---:mlm,mlp,mly.
 --- mlp        46.0mg   P<.0005 c  21.1mg 84.8mg   2/50   30/50
 liv MXA        60.0mg   P<.004     13.0mg 1.02gm  11/50    4/50                                                      liv:hpb,hpc. S
 liv hpc        60.0mg   P<.004     13.0mg 1.02gm  11/50    4/50                                                                   S
 for MXA        91.4mg   P<.0005 c  36.1mg 227.mg   1/50   10/50                                                      for:sqc,sqp.
 --- MXA        111.mg   P<.002     24.5mg 1.19gm   2/50    3/50                                                      ---:mlm,mly. S
 zym car        135.mg   P<.005  e  25.1mg 3.58gm   0/50    2/50
 zym MXA        135.mg   P<.005     25.1mg 3.58gm   1/50    2/50                                                      zym:ade,car. S
 for sqc        136.mg   P<.0005    41.3mg 533.mg   0/50    6/50                                                                   S
 for sqp        284.mg   P<.002     97.1mg 1.71gm   1/50    4/50                                                                   S
 --- hcs        396.mg   P<.02   c  90.5mg n.s.s.   0/50    2/50
 bra ogm        403.mg   P<.05   c  65.7mg n.s.s.   0/50    1/50
 kid rua        961.mg   P<.1    c  157.mg n.s.s.   0/50    1/50
 bra onm        no dre   P=1.       n.s.s. n.s.s.   0/50    0/50
 --- hem        no dre   P=1.       n.s.s. n.s.s.   1/50    0/50
 TBA MXB        12.5mg   P<.0005    6.22mg 24.0mg  44/50   49/50
 liv MXB        23.8mg   P<.0005    8.28mg 77.1mg  21/50   13/50                                                  liv:hpa,hpc,nnd.
 lun MXB        13.4mg   P<.0005    5.01mg 36.8mg  21/50   17/50                                                      lun:a/a,a/c.
874  M m b6c inh  3m24 TR434d : ()                   0    45.2mg
 MXB MXB        7.00mg   P<.0005    3.95mg 14.6mg  38/50   49/50   ---:hcs,mlm,mlp,mly; bra:ogm,onm; for:sqc,sqp; hag:adc,ade,adi,
                                                                     anb; hea:hes; kid:rua; liv:hpa; lun:a/a,a/c,adc; pre:car,cnb. C
 lun MXA        8.59mg   P<.0005 c  4.42mg 20.5mg  21/50   28/50                                                  lun:a/a,a/c,adc.
 hag MXA        11.7mg   P<.0005 c  5.73mg 27.0mg   6/50   23/50                                              hag:adc,ade,adi,anb.
 lun MXA        14.1mg   P<.0005    6.87mg 35.0mg   5/50   18/50                                                      lun:a/c,adc. S
 hag MXA        14.9mg   P<.0005    7.17mg 36.3mg   6/50   20/50                                                      hag:ade,anb. S
 liv MXA        15.1mg   P<.0005    7.17mg 45.5mg  21/50   24/50                                                      liv:hpa,hpc. S
 liv MXA        15.1mg   P<.0005    7.17mg 45.5mg  21/50   24/50                                                  liv:hpa,hpb,hpc. S
 --- MXA        16.9mg   P<.0005    7.78mg 44.7mg   2/50   14/50                                                      ---:hem,hes. S
 lun a/a        17.1mg   P<.0005    7.56mg 68.5mg  18/50   17/50                                                                   S
 liv hpa        17.9mg   P<.0005 c  7.86mg 58.2mg  13/50   19/50
 --- hes        21.9mg   P<.0005    9.92mg 58.7mg   1/50   12/50                                                                   S
 liv MXA        23.4mg   P<.0005    9.57mg 99.0mg  11/50   14/50                                                      liv:hpb,hpc. S
 liv hpc        23.4mg   P<.0005    9.57mg 99.0mg  11/50   14/50                                                                   S
 --- MXA        26.2mg   P<.0005    12.4mg 61.8mg   4/50   24/50                                              ---:hcs,mlm,mlp,mly. S
 hea hes        32.6mg   P<.0005 c  12.4mg 108.mg   0/50    7/50
 --- MXA        34.9mg   P<.0005 c  16.2mg 86.4mg   4/50   22/50                                                  ---:mlm,mlp,mly.
 for sqc        43.4mg   P<.0005    13.4mg 264.mg   0/50    4/50                                                                   S
 for MXA        44.8mg   P<.0005 c  14.6mg 226.mg   1/50    7/50                                                      for:sqc,sqp.
 --- hem        45.8mg   P<.003     13.7mg 449.mg   1/50    4/50                                                                   S
 hag MXA        63.5mg   P<.0005    19.2mg 358.mg   0/50    4/50                                                      hag:adc,adi. S
 --- mlp        66.8mg   P<.0005 c  33.3mg 175.mg   2/50   17/50
 --- hcs        91.1mg   P<.007  c  21.1mg 2.84gm   0/50    2/50
 pre MXA        119.mg   P<.002     43.9mg 550.mg   0/50    5/50                                                  pre:ade,car,cnb. S
 pre MXA        167.mg   P<.004  c  56.7mg 1.32gm   0/50    4/50                                                      pre:car,cnb.
 --- MXA        78.1mg   P<.02      21.6mg n.s.s.   2/50    5/50                                                      ---:mlm,mly. S
 for sqp        117.mg   P<.02      27.3mg n.s.s.   1/50    4/50                                                                   S
 kid rua        201.mg   P<.06   c  32.8mg n.s.s.   0/50    1/50
 bra ogm        230.mg   P<.03   c  51.0mg n.s.s.   0/50    2/50
 zym car        336.mg   P<.04   e  79.6mg n.s.s.   0/50    2/50
 bra onm        394.mg   P<.05   c  93.4mg n.s.s.   0/50    2/50
 zym MXA        223.mg   P<.2       34.2mg n.s.s.   1/50    2/50                                                      zym:ade,car.
 TBA MXB        6.92mg   P<.0005    3.87mg 15.0mg  44/50   49/50
 liv MXB        15.1mg   P<.0005    7.17mg 45.5mg  21/50   24/50                                                  liv:hpa,hpc,nnd.
 lun MXB        8.59mg   P<.0005    4.42mg 20.5mg  21/50   28/50                                                      lun:a/a,a/c.
875  R f cdr inh 24m24 1829                          0    166.mg  1.32gm                                   Owen;amih,48,407-413;1987
 mgl mix e      133.mg \ P<.0005 +  78.0mg 341.mg  50/100  79/100 (81/100)
 mgl ben e      182.mg \ P<.0005    110.mg 428.mg  32/100  64/100 (55/100)
 thy fca e      8.27gm * P<.0005    4.26gm 24.8gm   0/100   2/100  10/100
 mgl mal e      7.72gm * P<.07      2.91gm n.s.s.  18/100  15/100  26/100
 tba tum e      no dre   P=1.       893.mg n.s.s.  97/100  98/100  94/100
876  R m cdr inh 26m26 1829                          0    116.mg  927.mg
 tes ldc e      7.55gm * P<.003  +  3.58gm 52.9gm   0/100   3/100   8/100
 pan exa e      9.31gm * P<.006     3.98gm 136.gm   3/100   1/100  10/100
 tba tum e      1.47gm * P<.08      550.mg n.s.s.  84/100  70/100  87/100
Mutagenicity in Salmonella: positive
SMILES Code for 1,3-Butadiene: C=CC=C
InChI Code for 1,3-Butadiene: InChI=1/C4H6/c1-3-4-2/h3-4H,1-2H2
Source for SMILES and InChI: USEPA Distributed Structure-Searchable Toxicity (DSSTox) Database
Chemical Structure for 1,3-Butadiene: Chemical Structure
Source for structure: National Library of Medicine ChemIDPlus

See full CPDB Summary Table on 1547 chemicals. See Full CPDB for all results on 6540 experiments of 1547 chemicals.

A complete list of CPDB chemicals, which is searchable by name or by CAS number, is available here.

For a compendium of CPDB results organized by target organ, which lists all chemicals in each species that induced tumors in each of 35 organs, see Summary Table by Target Organ.

The CPDB is available in several formats that permit printing and downloading into spreadsheets and statistical databases.

  1. A plot of the CPDB presents results of 1547 experiments on 6540 chemicals in an easily readable format that has been used in publications of the CPDB.
  2. A Screen version plot for use on a single computer screen, with the same data.
  3. Excel version of the same data.
  4. Tab-separated versions of the same data, which can be easily read into databases.

A Supplementary Dataset gives details on dosing and survival for each experiment.

Relatively precise estimates of the lower confidence limit on the TD10 (LTD10) are readily calculated from the TD50 and its lower confidence limit, which are reported in the CPDB. For researchers and regulatory agencies interested in LTD10 values, we provide them in an Excel spreadsheet.

PDF versions of our publications of analyses using the CPDB are available, organized by year and by research topic.

Carcinogenic Potency Database Project (CPDB) Home Page
For more information about this Web Page, contact slone.cpdb@gmail.com.
Last updated: October 3, 2007